The erythropoiesis-stimulating agents available to treat pathological anemia, commonly associated with end stage renal disease and cancer chemotherapy, such as Aranesp, Procrit, Epogen and Neorecormon, are biologic derivatives or various formulations derived from the same protein, erythropoietin (EPO). This evidence concerns the gene EPO and anemia (phenotype).